CD47 is a transmembrane protein that possesses the ability to inhibit macrophage phagocytosis, enabling immune system evasion. While CD47 overexpression is associated with a poor prognosis in solid malignancies, data on its prognostic significance in lymphomas are inconsistent. This study aimed to evaluate the clinical and prognostic significance of CD47 expression in patients with large B-cell lymphoma (LBCL). In this study biopsy specimens from 146 patients diagnosed with LBCL and treated with immunochemotherapy were analyzed. CD47 expression was assessed using standard immunohistochemical methods. A high level of CD47 expression was detected in 30 (20.5%) patients. High CD47 expression was more frequently observed in patients with high β2-microglobulin levels and extranodal disease compared to nodal LBCL. No significant difference in CD47 expression was observed between gastrointestinal LBCL and other extranodal localizations. CD47 positivity had no significant influence on progression-free survival (PFS) and overall survival (OS); however, a trend toward shorter PFS and OS was noted (p = 0.099 and p = 0.149, respectively). The median PFS and OS were 27 and 37 months, respectively, in patients with high CD47 expression, while the median PFS and OS were not reached in the group of CD47 negative patients. Although CD47 expression was not an independent predictor of survival, the magnitude and direction of the observed hazard ratios suggest a potentially clinically meaningful effect.
Abstract Background Microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH) represent the most severe phenotypes of reperfusion injury following primary PCI in ST-elevation myocardial infarction (STEMI). Their structural and clinical determinants, as well as the incremental prognostic contribution of cardiac magnetic resonance (CMR), remain incompletely defined in contemporary practice. Purpose To identify independent predictors of MVO and IMH and quantify the incremental predictive value of CMR-derived parameters beyond clinical and angiographic assessment. Methods In consecutive STEMI patients from the multicenter SINERGY-ACUTE cohort undergoing early CMR (n=268), MVO was assessed by late gadolinium enhancement and IMH by T2* imaging. Penalized multivariable logistic regression was applied to account for collinearity. Hierarchical models were constructed: (1) clinical, (2) clinical + angiographic, and (3) clinical + angiographic + CMR (infarct size, LV volumes, MVO/IMH). Discrimination was evaluated using AUC with 95% CI and DeLong testing. Incremental value was assessed by ΔAUC, Net Reclassification Improvement (NRI), and Integrated Discrimination Improvement (IDI). Internal validation was performed using bootstrap resampling. Results A total of 268 STEMI patients with CMR was included in the study with the median age of 60 years. MVO was detected in 40.8%, while IMH was detected in 19% of patients. Independent predictors of MVO were infarct size (per 5% increase: OR 1.26, 95% CI 1.17–1.36; p<0.001), LVESV (per 10 mL: OR 1.18, 95% CI 1.10–1.27; p<0.001), angiographic no-reflow (OR 1.94, 95% CI 1.42–2.66; p<0.001), and log peak troponin (OR 1.41, 95% CI 1.22–1.63; p<0.001). Clinical AUC was 0.63 versus 0.86 for the CMR-integrated model (ΔAUC +0.23; p<0.001; NRI 0.38; IDI 0.14). Independent predictors of IMH were infarct size (OR 1.31 per 5%; p<0.001), LVESV (OR 1.22 per 10 mL; p<0.001), presence of MVO (OR 2.48; p<0.001), and log NT-proBNP (OR 1.47; p<0.001). Clinical AUC improved from 0.67 to 0.91 with CMR integration (ΔAUC +0.24; p<0.001; NRI 0.44; IDI 0.18). Bootstrap-corrected AUC values remained robust with preserved calibration. Conclusions Infarct size is the dominant structural determinant of both MVO and IMH after STEMI. Notably, MVO was independently associated with peak troponin, reflecting the magnitude of acute myocardial necrosis, whereas IMH was independently linked to NT-proBNP, consistent with greater hemodynamic stress and early ventricular dysfunction. CMR-derived parameters provide substantial and statistically robust incremental discrimination beyond clinical and angiographic assessment, supporting systematic early imaging-based phenotyping of reperfusion injury in contemporary STEMI care.
Despite major advances in guideline-directed medical therapy (GDMT), many patients with heart failure with reduced ejection fraction (HFrEF) remain symptomatic, with persistent limitations in functional capacity and health status, underscoring the need for adjunctive therapeutic strategies. Direct cardiac microcurrent (C-MIC) therapy is a non-excitatory bioelectrical intervention device to modulate myocardial remodeling rather than rhythm or acute contractility. C-MIC therapy influence myocardial biology, including pathways related to fibrosis, inflammation, and cellular homeostasis by delivering continuous, subthreshold direct current. Preclinical studies across cardiomyocytes, animal models, and cardiac fibroblasts suggest that microcurrent exposure may attenuate profibrotic signaling, regulate extracellular matrix turnover, and improve calcium handling, providing a mechanistic rationale for reverse remodeling. Early clinical experience, including first-in-human studies and a randomized trial in carefully selected patients with non-ischemic HFrEF, demonstrates feasibility and a consistent signal of improvement in left ventricular function, functional capacity, and patient-reported outcomes. However, the current evidence base remains limited by small sample size, open-label designs, and the absence of sham-controlled evaluation. All available clinical data are derived from surgically implanted systems, and the effectiveness of less invasive configurations remains uncertain. Accordingly, C-MIC should be considered an investigational therapy. Future development will require rigorous mechanistic validation, optimization of device programming and delivery parameters, and confirmation of efficacy in adequately powered, sham-controlled trials to define its role in contemporary HF management.
Abstract Background Despite successful reperfusion, early heart failure (HF) remains frequent after STEMI. We assessed whether a multidimensional cardiac magnetic resonance (CMR) evaluation at discharge identifies patients at risk for 6-month HF-related events in a real-world cohort. Methods Consecutive STEMI patients undergoing discharge CMR were analyzed. The 6-month composite endpoint included HF hospitalization, HF-related emergency visit, NYHA class ≥ II, or LVEF <50% at follow-up. CMR parameters reflected complementary pathophysiological domains: infarct size (structural injury), global radial strain (mechanical dysfunction), and left atrial biplane ejection fraction (atrial functional reserve). Hierarchical logistic modeling and bootstrap validation were performed. Results Among 115 patients with complete CMR and follow-up data, 21 (18%) experienced the composite HF endpoint at 6 months. In univariable analysis, larger infarct size, lower global radial strain (GRS), and reduced left atrial ejection fraction (LAEF) were all associated with increased HF risk. In the final multivariable model, infarct size remained independently associated with HF events (OR 1.08 per 1% increase; p=0.008), corresponding to an 8% increase in odds per 1% increment. Higher global radial strain was independently protective (OR 0.88 per 1% increase; p=0.023), translating into a 12% reduction in odds per 1% increment. Although left atrial ejection fraction was associated with HF risk in univariable analysis, it did not retain independent significance after adjustment (OR 0.95 per 1% increase; p=0.082), suggesting partial overlap with ventricular injury and mechanical impairment. Hierarchical modeling demonstrated incremental discrimination with the sequential addition of atrial functional reserve and radial mechanics beyond infarct size. The multivariable model showed good explanatory power (Nagelkerke R² = 0.405) and favorable discrimination (AUC 0.862). Conclusions Early post-STEMI HF is not driven by infarct size alone. Structural injury, impaired radial mechanics, and reduced atrial functional reserve represent complementary determinants of early structural–functional HF progression. Patients combining larger infarcts, impaired radial contraction, and reduced atrial functional reserve represent a high-risk phenotype for early heart failure progression after STEMI. Multidimensional discharge CMR may refine post-infarction risk stratification in routine clinical practice.TablesGraphical Abstract
It is widely recognized that not only high blood pressure (BP) but also increased resting heart rate (RHR) impairs prognosis in patients with arterial hypertension (HTN). This study aims to answer 5 questions regarding the guidelines on HTN: 1. ‘Is the significance of high RHR in HTN acknowledged?’; 2. ‘Is there a recommendation to decrease RHR in chronic antihypertensive treatment?’; 3. ‘Which antihypertensive medication is preferred to diminish high RHR in HTN patients?’ 4. ‘What is the treatment threshold value of RHR in patients with HTN?’ and 5. ‘Is there a recommendation for target RHR in chronic treatment of HTN?’. The significance of RHR and the treatment approach to it are scarcely mentioned in the key publications—the guidelines on HTN—and there is no obvious firm argument to omit recommendations related to threshold and target RHR in HTN patients. On the contrary, there are at least five (major) reasons for addressing increased RHR in HTN guidelines. The vast majority of HTN guidelines do not acknowledge the significance of RHR elevation (as a cardiovascular risk factor). This discrepancy affects as much as 30-38% of the hypertensive population (that is, global > 1.28 billion adults – according to the World Health Organization). We highlight the need for improvement in the forthcoming guidelines that (in the current versions) do not explain the importance of RHR in HTN. Additional investigations are needed to confirm whether reducing high resting heart rate in HTN patients improves prognosis.